Chlamydia-activated B cell platforms and methods thereof
AssigneeOhio State Innovation Foundation
InventorsThomas Cherpes, Rodolfo Vicetti Miguel
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a Chlamydia-activated B cell (CAB) platform. Also disclosed is a method of enhancing a population of B cells, comprising exposing said B cells to Chlamydia spp. under conditions suitable to enhance the population of B cells, such that expansion and differentiation of said B cells takes place, and said B cells are exposed or crosslinked to an antigen. Also disclosed are methods of producing said CABs, and treating a subject in need thereof with said CABs.
Claims6
An ex vivo or in vitro platform for creating a cellular vaccine comprising activated, antigen-presenting cells (APCs) against an antigen of interest, wherein the platform comprises:
- a. a whole, inactivated Chlamydia spp. bacterium;
- b. a population of B cells;
- and
- c. the antigen of interest, wherein the antigen is not derived from a Chlamydia spp.;
- wherein the population of B cells are exposed to the whole, inactivated Chlamydia spp. bacterium, thereby forming Chlamydia-activated B cells (CABs);
- wherein said CABs are then exposed or crosslinked to the antigen of interest, thereby forming a cellular vaccine comprising APCs.
Dependencies are inferred from the claim text.